Epigenetic Priming with Azacitidine Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies.
Pre-transplant treatment with azacitidine showed encouraging survival outcomes and identified a molecular marker linking treatment response to relapse prevention in blood cancer patients.
This Phase II study (n=39) demonstrates azacitidine pre-transplant priming is feasible with encouraging OS/PFS, and pharmacodynamic data link azacitidine-induced CD34+ DNA hypomethylation to improved relapse-free survival—establishing an epigenetic biomarker hypothesis. Findings support randomized evaluation of epigenetic priming strategies in high-risk myeloid alloHCT.
What the study was
- Study design
- Open-label prospective Phase II study; azacitidine in reduced-intensity conditioning before alloHCT; pharmacodynamic CD34+ DNA methylation evaluation.
- Population
- 39 patients with AML (85%) or high/very high-risk MDS (23% TP53-mutated) undergoing alloHCT (Weill Cornell Medicine).
- Sample size
- 39
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Transplantation and Cellular Therapy
Why it surfaced
Prospective Phase II evidence for epigenetic priming in high-risk myeloid alloHCT with pharmacodynamic biomarker data; major unmet need for TP53-mutated disease.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.